GSK has completed the demerger of its Consumer Healthcare business from the overall group, leading to the operational launch of Haleon as an independent company.
The newly-listed Haleon said it is “100% focused on consumer health” and “driven by its purpose to deliver better everyday health with humanity”. The company – which owns brands such as Sensodyne, Voltarol, and Panadol – stated that it will continue to develop category-leading brands that address real consumer health needs, while focusing on future innovation across its entire portfolio.
Haleon said its launch comes at a time when the consumer healthcare market is set for expansion (+3-4% per annum over the medium-term), adding that it expects to deliver medium-term annual organic revenue growth of 4-6%. It plans to utilise a two-pronged approach – working to remove barriers to better everyday health; and aiming to empower 50 million people a year by 2025 to be more included in opportunities for better everyday health. The company added that its competitive advantage lies “in its ability to blend deep human understanding and trusted science in the products it creates”.
Brian McNamara, CEO of Haleon, said: “Guided by our clear purpose and with a world class portfolio of brands that people know and trust, we stand ready to help address consumer needs and make better everyday health more achievable, inclusive and sustainable. Consumer health has never been more important than it is today, and I am delighted that Haleon, as an independent company, is ready to pursue our ambitions. Today follows a huge amount of effort, planning and collaboration by our dedicated colleagues all around the world.”
Tess Player, VP Global Head of Expert/Health Professionals, added: “The arrival of Haleon heralds a new opportunity to use our laser focus on consumer health to tackle some of the big global challenges standing in the way of better everyday health. Partnering with health professionals is a top priority and we’ll work tirelessly to support them in solving these challenges and giving excluded groups access to them in ways they historically haven’t had. We’re spear-heading initiatives, both independently and in partnership, to better understand the drivers of health inclusivity, and inform actions across key areas such as health literacy, an area we know health professionals have a key role to play.”
NAM Implications:
- Haleon is poised to generate above-market, medium-term annual organic revenue growth of 4% to 6%.
- i.e. Stock market pressure to excel.
- …which, added to GSK ability to focus 100% on Haleon.
- …makes for a formidable (Enterprise value of £33bn to £48bn) player in these categories.
